Literature DB >> 25096166

Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection.

Rosa Polo Rodríguez, María José Galindo Puerto, Carlos Dueñas, Carmen Gómez Candela, Vicente Estrada, Noemí G P Villar, Jaime Locutura, Ana Mariño, Javier Pascua, Rosario Palacios, Miguel Ángel Von Wichmman, Julia Álvarez, Victor Asensi, José Lopez Aldeguer, Fernando Lozano, Eugenia Negredo, Enrique Ortega, Enric Pedrol, Félix Gutiérrez, Jesús Sanz Sanz, Esteban Martínez Chamorro.   

Abstract

The importance of the metabolic disorders and their impact on patients with HIV infection requires an individualized study and continuous updating. HIV patients have the same cardiovascular risk factors as the general population. The HIV infection per se increases the cardiovascular risk, and metabolic disorders caused by some antiretroviral drugs are added risk factors. For this reason, the choice of drugs with a good metabolic profile is essential. The most common metabolic disorders of HIV infected-patients (insulin resistance, diabetes, hyperlipidemia or osteopenia), as well as other factors of cardiovascular risk, such as hypertension, should also be dealt with according to guidelines similar to the general population, as well as insisting on steps to healthier lifestyles. The aim of this document is to provide a query tool for all professionals who treat HIV-patients and who may present or display any metabolic disorders listed in this document.
Copyright © 2014 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Alteraciones metabólicas; Cardiovascular risk; HIV infection; Infección por VIH; Metabolic disorders; Riesgo cardiovascular

Mesh:

Substances:

Year:  2014        PMID: 25096166     DOI: 10.1016/j.eimc.2014.05.018

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  3 in total

Review 1.  Stimulating high impact HIV-related cardiovascular research: recommendations from a multidisciplinary NHLBI Working Group on HIV-related heart, lung, and blood disease.

Authors:  Monica R Shah; Nakela Cook; Renee Wong; Priscilla Hsue; Paul Ridker; Judith Currier; Susan Shurin
Journal:  J Am Coll Cardiol       Date:  2015-02-24       Impact factor: 24.094

2.  Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.

Authors:  Alper Daskapan; Desie Dijkema; Dorien A de Weerd; Wouter F W Bierman; Jos G W Kosterink; Tjip S van der Werf; Jan-Willem C Alffenaar; Ymkje Stienstra
Journal:  Br J Clin Pharmacol       Date:  2017-08-01       Impact factor: 4.335

3.  Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk.

Authors:  José M Gatell; Lambert Assoumou; Graeme Moyle; Laura Waters; Margaret Johnson; Pere Domingo; Julie Fox; Esteban Martinez; Hans-Jürgen Stellbrink; Giovanni Guaraldi; Mar Masia; Mark Gompels; Stephane De Wit; Eric Florence; Stefan Esser; François Raffi; Anton L Pozniak
Journal:  AIDS       Date:  2017-11-28       Impact factor: 4.177

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.